Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:CYTK NASDAQ:PRAX NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$129.76-2.2%$118.43$5.69▼$148.83$10.35B0.691.11 million shs924,081 shsCYTKCytokinetics$73.44-4.3%$68.95$30.55▼$80.20$9.13B0.422.19 million shs739,461 shsPRAXPraxis Precision Medicines$337.29-3.6%$326.47$37.19▼$366.52$9.43B2.71442,272 shs92,601 shsTARSTarsus Pharmaceuticals$58.29-1.9%$65.26$38.51▼$85.25$2.51B0.49606,569 shs165,593 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.72%+12.99%+17.26%+2,110.50%CYTKCytokinetics0.00%-0.23%+19.99%+24.96%+148.58%PRAXPraxis Precision Medicines0.00%+1.87%+9.77%+5.86%+807.13%TARSTarsus Pharmaceuticals0.00%-4.59%-6.62%-23.29%+38.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$129.76-2.2%$118.43$5.69▼$148.83$10.35B0.691.11 million shs924,081 shsCYTKCytokinetics$73.44-4.3%$68.95$30.55▼$80.20$9.13B0.422.19 million shs739,461 shsPRAXPraxis Precision Medicines$337.29-3.6%$326.47$37.19▼$366.52$9.43B2.71442,272 shs92,601 shsTARSTarsus Pharmaceuticals$58.29-1.9%$65.26$38.51▼$85.25$2.51B0.49606,569 shs165,593 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.72%+12.99%+17.26%+2,110.50%CYTKCytokinetics0.00%-0.23%+19.99%+24.96%+148.58%PRAXPraxis Precision Medicines0.00%+1.87%+9.77%+5.86%+807.13%TARSTarsus Pharmaceuticals0.00%-4.59%-6.62%-23.29%+38.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.155.70% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3035.21% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$592.6775.71% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6755.56% UpsideCurrent Analyst Ratings BreakdownLatest TARS, ABVX, PRAX, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026PRAXPraxis Precision Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/26/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$131.005/26/2026PRAXPraxis Precision Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,245.005/20/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$99.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy5/13/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$700.00 ➝ $715.005/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.005/11/2026CYTKCytokinetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$136.00 ➝ $140.005/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ACYTKCytokinetics$88.04M103.80N/AN/A($5.39) per share-13.63PRAXPraxis Precision Medicines$8.55M1,099.84N/AN/A$34.85 per share9.68TARSTarsus Pharmaceuticals$451.36M5.56N/AN/A$8.09 per share7.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.14N/A19.96N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest TARS, ABVX, PRAX, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25CYTKCytokineticsN/A4.214.21PRAXPraxis Precision MedicinesN/A15.8815.88TARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%CYTKCytokineticsN/APRAXPraxis Precision Medicines67.84%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ACYTKCytokinetics2.60%PRAXPraxis Precision Medicines2.70%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.69 millionN/ANot OptionableCYTKCytokinetics250124.43 million121.20 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableTARS, ABVX, PRAX, and CYTK HeadlinesRecent News About These CompaniesTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comUBS Group AG Has $5.48 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSMay 21, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMJohn Cena hops into the ring to fight demodex blepharitis for Tarsus PharmaceuticalsMay 19, 2026 | mmm-online.comMTarsus Pharmaceuticals, Inc. $TARS Stake Raised by TimesSquare Capital Management LLCMay 19, 2026 | marketbeat.comTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comCena was diagnosed with Demodex blepharitis, which he admittedly "didn't even know existed"May 14, 2026 | yahoo.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansMay 14, 2026 | globenewswire.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsMay 13, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Tarsus Pharmaceuticals (TARS)May 11, 2026 | theglobeandmail.comIs It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?May 11, 2026 | finance.yahoo.comWhat is HC Wainwright's Estimate for TARS Q2 Earnings?May 11, 2026 | marketbeat.comLifesci Capital Has Negative Estimate for TARS Q2 EarningsMay 11, 2026 | marketbeat.comVanguard Group Inc. Purchases 127,470 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 10, 2026 | marketbeat.comF m Investments LLC Makes New $3.21 Million Investment in Tarsus Pharmaceuticals, Inc. $TARSMay 10, 2026 | marketbeat.comWhat is HC Wainwright's Estimate for TARS FY2027 Earnings?May 8, 2026 | marketbeat.comLifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)May 8, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The Stars Are Aligning For Apple: Get Ready for $300By Sam Quirke | May 11, 2026TARS, ABVX, PRAX, and CYTK Company DescriptionsAbivax NASDAQ:ABVX$129.76 -2.88 (-2.17%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Cytokinetics NASDAQ:CYTK$73.44 -3.32 (-4.32%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$337.29 -12.68 (-3.62%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$58.28 -1.12 (-1.88%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
